Syntiron, LLC’s mission is the prevention and treatment of human disease resulting from bacterial infection. We are developing several vaccines; most notably, a vaccine to prevent infection by staphylococcus aureus (including MRSA). Other vaccines in development are for protection against Salmonella, ETEC, Shigella, Yersinia, Bacillus anthracis, Burkholderia, and Clostridium. Syntiron is also working on a therapeutic antibody treatment for individuals infected with Staphylococcus.